ALVOTECH

NASDAQ: ALVO (Alvotech)

Kemas kini terakhir: 12 May, 9:02AM

9.68

0.30 (3.20%)

Penutupan Terdahulu 9.38
Buka 10.12
Jumlah Dagangan 505,913
Purata Dagangan (3B) 149,645
Modal Pasaran 2,921,482,240
Harga / Pendapatan (P/E Ke hadapan) 43.67
Harga / Jualan (P/S) 4.34
Julat 52 Minggu
7.35 (-24%) — 14.65 (51%)
Margin Keuntungan -47.13%
Margin Operasi (TTM) 9.32%
EPS Cair (TTM) -0.870
Pertumbuhan Hasil Suku Tahunan (YOY) 177.40%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -65.50%
Nisbah Semasa (MRQ) 2.35
Aliran Tunai Operasi (OCF TTM) -236.84 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -350.88 M
Pulangan Atas Aset (ROA TTM) 4.06%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Menurun Bercampur
Drug Manufacturers - Specialty & Generic (Global) Menurun Bercampur
Stok Alvotech Bercampur Menurun

AISkor Stockmoo

1.6
Konsensus Penganalisis -2.0
Aktiviti Orang Dalam NA
Volatiliti Harga 1.5
Purata Bergerak Teknikal 5.0
Osilator Teknikal 2.0
Purata 1.63

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ALVO 3 B - - -
NBIX 12 B - 40.88 4.74
LNTH 6 B - 15.19 6.42
KNSA 2 B - - 4.29
HROW 951 M - - 13.08
CRON 782 M - 14.50 0.650

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.

Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 63.80%
% Dimiliki oleh Institusi 6.66%

Pemilikan

Nama Tarikh Syer Dipegang
Littlejohn & Co Llc 31 Dec 2024 1,318,534
Lodbrok Capital Llp 31 Dec 2024 181,587
Oaktree Fund Advisors, Llc 31 Dec 2024 116,294
23.2023.2019.6019.6016.0016.0012.4012.408.808.80Harga Sasaran MedianQ3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
28 May 2025 Pengumuman Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe
28 May 2025 Pengumuman Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe
19 May 2025 Pengumuman Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm
19 May 2025 Pengumuman Trading in Alvotech’s Shares on Nasdaq Stockholm Commences Today
16 May 2025 Pengumuman Alvotech Announces the Outcome of the Offering in Connection with the Company’s Listing on Nasdaq Stockholm
09 May 2025 Pengumuman Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada
09 May 2025 Pengumuman Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada  
09 May 2025 Pengumuman Transactions of Managers and Closely Associated Persons
08 May 2025 Pengumuman Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm
07 May 2025 Pengumuman Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025
07 May 2025 Pengumuman Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025
07 May 2025 Pengumuman Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
07 May 2025 Pengumuman Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
05 May 2025 Pengumuman Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
05 May 2025 Pengumuman Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
02 May 2025 Pengumuman Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)
02 May 2025 Pengumuman Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT
27 Mar 2025 Pengumuman Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer
27 Mar 2025 Pengumuman Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer
26 Mar 2025 Pengumuman UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
26 Mar 2025 Pengumuman UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
26 Mar 2025 Pengumuman Alvotech Reports Record Results for 2024 and Provides Business Update
26 Mar 2025 Pengumuman Alvotech Reports Record Results for 2024 and Provides Business Update
20 Mar 2025 Pengumuman Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
20 Mar 2025 Pengumuman Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
18 Mar 2025 Pengumuman Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
18 Mar 2025 Pengumuman Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
18 Mar 2025 Pengumuman Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
07 Mar 2025 Pengumuman Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida
07 Mar 2025 Pengumuman Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida
Papar semua
10.9910.9910.2610.269.539.538.808.808.068.06May 14May 14May 15May 15May 16May 16May 19May 19May 20May 20May 21May 21May 22May 22May 23May 23

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.4000.4000.2000.200-0.000-0.000-0.200-0.200-0.400-0.400MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda